{"id":"W4362588741","doi":"10.1016/s1556-0864(23)00424-0","title":"170P Preliminary results from LUMINANCE: A phase IIIb, single-arm study of 1L durvalumab (D) + platinum-etoposide (EP) for patients with extensive-stage SCLC (ES-SCLC)","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Symphogen; GlaxoSmithKline; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Etoposide; Internal medicine; Phases of clinical research; Oncology; Chemotherapy; Cancer; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00185552,0.001652532,0.002061189,0.0003963724,0.0005176917,0.001029531,0.0009781301,0.001425895,0.005217913],"category_scores_gemma":[0.00117103,0.0005399658,0.001772946,0.0004197701,0.0008961846,0.0008914763,0.0003174341,0.003294207,0.001400422],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00111348,"about_ca_system_score_gemma":0.002131012,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003303009,"about_ca_topic_score_gemma":0.009706574,"domain_scores_codex":[0.9993887,0.0003355579,0.00002260401,0.00006628,0.00004562645,0.000141231],"domain_scores_gemma":[0.9991591,0.00020122,0.0001032847,0.00006574596,0.00004852785,0.000422186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7990907,0.04049636,0.005135063,0.0008972036,0.00198949,0.0002723355,0.0003180214,0.001977731,0.03523339,0.0003451767,0.007899945,0.1063445],"study_design_scores_gemma":[0.6809003,0.2970719,0.01352899,0.00004817294,0.0007629783,0.0001685709,0.00006479015,0.0006311555,0.002567631,0.0002722785,0.003950885,0.00003230695],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9810798,0.004027168,0.0009884061,0.001731957,0.0003028903,0.003044142,0.004274947,0.0002000555,0.004350541],"genre_scores_gemma":[0.9710071,0.004153252,0.003582486,0.002708618,0.0004765841,0.004127411,0.006774282,0.0001155647,0.007054662],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005217913,"threshold_uncertainty_score":0.01745564,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06322569750506297,"score_gpt":0.4574548974330709,"score_spread":0.394229199928008,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}